RE:RE:Chart of the day!!!!!!!!!!!!!!!! Prothena.So, profitoffacts, fit
this article into your discussion of Prothena.
Is there a case to be made that PRX012 might be, could be, an xB3 drug?
Do a search on when PRX012 was first revealed? Interesting? No?
How does the information in the article fit with Bioasis's very much confusing March/21 goings-on with Prothena's options extensions?
Why is so low a dose of PRX012 needed? Subcutaneous? Slow delivery, still beats aducanumab?
If it's not an xB3 drug, then why has Prothena suddenly brought it out? Is there a future in the treatment of AD by amyloid beta drugs? Is Prothena making hay while the sun shines? If it's not an xB3 drug, has Prothena altogether abandoned its pursuit of an xB3 amyloid-beta drug, if that actually was the exclusive xB3 "target"
announced in 2018?
Why, sometime between March 17/21 and March 31/21, did Bioasis withdraw its Dec 31/22 extension on the options? Why were even those new dates changed again, so quickly? As you recently asked, is Prothena involved with Bioasis, at all?
Why is Prothena mentioned in the annual MD&A at the end of June and the word "Prothena" was stricken a month later from the Q1 MD&A?
You
skin this one, pilgrim, and I'll get you another!
Bear Claw